IN2014DN11269A - - Google Patents

Info

Publication number
IN2014DN11269A
IN2014DN11269A IN11269DEN2014A IN2014DN11269A IN 2014DN11269 A IN2014DN11269 A IN 2014DN11269A IN 11269DEN2014 A IN11269DEN2014 A IN 11269DEN2014A IN 2014DN11269 A IN2014DN11269 A IN 2014DN11269A
Authority
IN
India
Prior art keywords
cell
malignant cancers
cell malignant
lymphoma
cancers include
Prior art date
Application number
Other languages
English (en)
Inventor
Francesco Bertoni
Paola Bonetti
Original Assignee
Oncoethix Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncoethix Sa filed Critical Oncoethix Sa
Publication of IN2014DN11269A publication Critical patent/IN2014DN11269A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
IN11269DEN2014 2012-06-25 2013-06-25 IN2014DN11269A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261663885P 2012-06-25 2012-06-25
US201261670918P 2012-07-12 2012-07-12
PCT/EP2013/063313 WO2014001356A1 (en) 2012-06-25 2013-06-25 Method of treating lymphoma using thienotriazolodiazepine compounds

Publications (1)

Publication Number Publication Date
IN2014DN11269A true IN2014DN11269A (ja) 2015-10-09

Family

ID=48672651

Family Applications (1)

Application Number Title Priority Date Filing Date
IN11269DEN2014 IN2014DN11269A (ja) 2012-06-25 2013-06-25

Country Status (12)

Country Link
US (1) US20140018353A1 (ja)
EP (1) EP2863923B1 (ja)
JP (1) JP6265979B2 (ja)
KR (1) KR20150045423A (ja)
CN (1) CN105050605A (ja)
AU (1) AU2013283378B2 (ja)
BR (1) BR112014032105A2 (ja)
CA (1) CA2877434A1 (ja)
IN (1) IN2014DN11269A (ja)
MX (1) MX2014015986A (ja)
RU (1) RU2659171C2 (ja)
WO (1) WO2014001356A1 (ja)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3608317A1 (en) 2012-01-12 2020-02-12 Yale University Compounds & methods for the enhanced degradation of targeted proteins & other polypeptides by an e3 ubiquitin ligase
EA035469B1 (ru) 2013-03-15 2020-06-22 Инсайт Холдингс Корпорейшн Трициклические гетероциклы как ингибиторы белков бэт
JP2016523964A (ja) 2013-07-08 2016-08-12 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｂｅｔタンパク質阻害剤としての三環式複素環
US9795612B2 (en) * 2013-08-01 2017-10-24 Merck Sharp & Dohme Corp. Pharmaceutical formulation containing thienotriazolodiazepine compounds
CN105899212A (zh) * 2013-08-06 2016-08-24 翁科埃斯克斯有限公司 利用β溴结构域抑制剂治疗弥漫性大B细胞淋巴瘤(DLBCL)的方法
WO2015018522A1 (en) * 2013-08-06 2015-02-12 Oncoethix Sa Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl)
WO2015018520A1 (en) * 2013-08-06 2015-02-12 Oncoethix Sa A bet-brd inhibitor represents a novel agent for alk positive anaplastic large cell lymphoma
US9315501B2 (en) 2013-11-26 2016-04-19 Incyte Corporation Bicyclic heterocycles as BET protein inhibitors
US9399640B2 (en) 2013-11-26 2016-07-26 Incyte Corporation Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
EP3074018A1 (en) * 2013-11-27 2016-10-05 Oncoethix GmbH Method of treating leukemia using pharmaceutical formulation containing thienotriazolodiazepine compounds
US9309246B2 (en) 2013-12-19 2016-04-12 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
MX2016013851A (es) 2014-04-23 2017-07-14 Incyte Corp 1h-pirrolo[2,3-c]piridin-7(6h)-onas y pirazolo[3,4-c]piridin-7(6h) -onas como inhibidores de proteinas de bromodominio y extra terminal (bet).
EP3137086A4 (en) * 2014-05-02 2017-12-27 Oncoethix GmbH Method of treating resistant non-hodgkin lymphoma, medulloblastoma, and/or alk+non-small cell lung cancer using thienotriazolodiazepine compounds
KR20160145833A (ko) 2014-05-02 2016-12-20 온코에틱스 게엠베하 티에노트리아졸로디아제핀 화합물을 사용한 급성 골수성 백혈병 및/또는 급성 림프아구성 백혈병의 치료 방법
WO2015169951A1 (en) 2014-05-08 2015-11-12 Oncoethix Gmbh Method of treating triple-negative breast cancer using thienotriazolodiazepine compounds
US9901583B2 (en) 2014-06-13 2018-02-27 Oncoethix Gmbh Method of treating non-small cell lung cancer and/or small cell lung cancer using thienotriazolodiazepine compounds
EP3182976A1 (en) * 2014-08-19 2017-06-28 Oncoethix GmbH Methods of treating lymphoma using thienotriazolodiazepine compounds
EP3194406B8 (en) 2014-09-15 2021-03-31 Incyte Corporation Tricyclic heterocycles for use as bet protein inhibitors
KR101675984B1 (ko) * 2015-02-23 2016-11-14 한양대학교 에리카산학협력단 티에노디아제핀 유도체 또는 이의 약학적으로 허용가능한 염, 및 이를 유효성분으로 포함하는 약학적 조성물
MX2017011919A (es) 2015-03-18 2018-05-22 Arvinas Inc Compuestos y metodos para la degradacion mejorada de proteinas especificas.
WO2016176335A1 (en) 2015-04-27 2016-11-03 Concert Pharmaceuticals, Inc. Deuterated otx-015
EP3337476A4 (en) 2015-08-19 2019-09-04 Arvinas, Inc. COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF PROTEINS CONTAINING BROMODOMAIN
US20170121347A1 (en) 2015-10-29 2017-05-04 Incyte Corporation Amorphous solid form of a bet protein inhibitor
CR20220651A (es) 2016-06-20 2023-01-23 Incyte Corp FORMAS SOLIDAS CRISTALINAS DE UN INHIBIDOR DE BET (Divisional expediente 2019-0027.)
WO2019148055A1 (en) 2018-01-26 2019-08-01 Yale University Imide-based modulators of proteolysis and methods of use
CN108070562A (zh) * 2018-02-03 2018-05-25 金华市中心医院 一种“双打击”弥漫大b细胞淋巴瘤细胞系制备方法
WO2019199816A1 (en) 2018-04-13 2019-10-17 Arvinas Operations, Inc. Cereblon ligands and bifunctional compounds comprising the same
EP4077309A1 (en) 2019-12-19 2022-10-26 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994006802A1 (en) 1992-09-18 1994-03-31 Yoshitomi Pharmaceutical Industries, Ltd. Thienodiazepine compound and medicinal use thereof
EP0989131B1 (en) * 1996-09-13 2002-11-13 Mitsubishi Pharma Corporation Thienotriazolodiazepine compounds and medicinal uses thereof
KR101600634B1 (ko) * 2007-12-28 2016-03-07 미쓰비시 타나베 파마 코퍼레이션 항암제
BR122014024883A2 (pt) * 2010-05-14 2019-08-20 Dana-Farber Cancer Institute, Inc. Compostos no tratamento de neoplasia
JP5715241B2 (ja) * 2010-05-14 2015-05-07 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド 新生物、炎症性疾患、およびその他の障害を治療するための組成物および方法
WO2013033420A1 (en) * 2011-08-30 2013-03-07 Whitehead Institute For Biomedical Research Methods of downregulating translocated oncogene expression using bromodomain inhibitors

Also Published As

Publication number Publication date
EP2863923B1 (en) 2019-05-08
CN105050605A (zh) 2015-11-11
RU2659171C2 (ru) 2018-06-28
CA2877434A1 (en) 2014-01-03
US20140018353A1 (en) 2014-01-16
KR20150045423A (ko) 2015-04-28
WO2014001356A1 (en) 2014-01-03
JP6265979B2 (ja) 2018-01-24
BR112014032105A2 (pt) 2017-08-01
AU2013283378B2 (en) 2017-07-13
JP2015531747A (ja) 2015-11-05
AU2013283378A1 (en) 2015-01-29
MX2014015986A (es) 2016-02-11
EP2863923A1 (en) 2015-04-29
RU2015101106A (ru) 2016-08-10

Similar Documents

Publication Publication Date Title
IN2014DN11269A (ja)
MX2010003815A (es) Terapia de combinacion de un anticuerpo anti-cd20 de tipo ii con un agente activo anti-bcl-2.
PH12015500940A1 (en) Bruton`s tyrosine kinase inhibitors
MX370814B (es) Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
TN2015000174A1 (en) Pyrrolopyrimidine compounds as kinase inhibitors
GEP201706786B (en) Methods and drug products for treating alzheimer's disease
SG10201808102WA (en) Bicyclic heterocycle compounds and their uses in therapy
NZ631144A (en) Compositions and methods for transmucosal absorption
CL2012003604A1 (es) Compuestos heterociclicos derivados de piridina carboxamida sustituida; proceso de preparacion; composicion farmaceutica; combinacion farmaceutica; uso en el tratamiento de trastornos proliferativos celulares, enfermedad de parkinson, cancer, entre otros.
MX2011007589A (es) Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20.
AU2011328009A8 (en) Compounds and methods for treating pain
TN2012000414A1 (en) Forms of rifaximin and uses thereof
MX365525B (es) Compuestos que regulan la expresión de subunidades alfa de canales de sodio regulados por voltaje en enfermedades relacionadas con epilepsia mioclónica severa de la infancia.
MX2013010770A (es) Tratamiento de tumores solidos.
MX356210B (es) Formulaciones de polimero acrilico.
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
MX357502B (es) Derivados de pirrolotriazinona.
PH12014501829A1 (en) Bicyclic pyrazinone derivatives
MD4538C1 (ro) 1-Piperazino-3-fenil-indani deuteraţi pentru tratamentul schizofreniei
MX360409B (es) Terapia de combinacion de dosis fija para la enfermedad de parkinson.
CL2011002812A1 (es) Compuestos derivados de [1,2,4]triazolo[4,3-b]piridazinas; proceso de preparacion; y uso en el tratamiento del cancer a la prostata.
MX348412B (es) Métodos de usar sns-595 para el tratamiento de sujetos con cáncer con actividad reducida de brca2.
PH12015500399A1 (en) Azaindolines
MX2014014816A (es) Composicion farmaceutica para tratar inflamacion y dolor.
WO2012125871A3 (en) Aconitine compounds, compositions, uses, and preparation thereof